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ABSTRACT
OBJECTIVE: This study was aimed to investigate the effects of addiction to nicotine and morphine and their with-
drawal on coronary angiogenesis and serum NO concentrations in two-kidney one-clip hypertensive (2K1C) rats.
METHODS: Male hypertensive rats were divided into the two below groups: Group (1): Rats received saline for 
8 weeks (n = 8); Group (2): Rats received morphine and nicotine for 8 weeks (n = 32). At the end of 8 weeks, 
the groups (2) were divided into the four sub-groups, which three of them were treated with withdrawal drugs. 
Following treatments, blood pressure, heart rate, plasma renin activity (PRA), NO concentration and capillary 
density were measured.
RESULTS: Results showed that blood pressure was signifi cantly reduced in the addicted group when compared 
to non-addicted (p < 0.05). The withdrawal completely reversed blood pressure to the level observed pre-addic-
tion (p < 0.05). Coronary angiogenesis was signifi cantly lower in the addicted group in comparistion to normal 
(p < 0.05) but withdrawal of addiction did not improve angiogenesis. 
CONCLUSION: On the basis of the present fi ndings, it may be indicative that the risk of cardiovascular compli-
cations in addiction is concurrent to chronic hypertension, which shows the importance of early diagnosis and 
treatment in clinical condition (Fig. 4, Ref. 59). Text in PDF www.elis.sk.
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Introduction
Neovascularization or angiogenesis is described as a phe-
nomenon, in which new vessels are generated from pre-existing 
blood vessels. The event of angiogenesis occurs in response to 
angiogenic molecules such as chemokines and hypoxia that re-
sult from tissue injury (1).Angiogenesis is important in develop-
ment of cardiovascular system (2).Vascular endothelial function 
is well correlated with angiogenesis and the endothelium stimu-
lates the processes of vasodilation, infl ammation and vascular 
smooth cell proliferation by releasing nitric oxide (NO) (3). NO 
as a biological mediator, is involved in an array of physiological 
and pathophysiological processes in various organs. Potentially, 
NO is a regulator for neovascularization, which is evidenced by 
many studies. Accumulating data also are demonstrative that NO 
is closely involved in the regulation of systemic blood pressure (4). 
Hypertension is a well-established risk factor for cardiovascular 
disorders. It is also indicated that hypertension is associated with 
several vascular abnormalities, including endothelial dysfunction, 
microvascular rarefaction and remodeling (5, 6). Hypertension is 
associated with defected blood vessel growth (6, 7), so that im-
paired angiogenesis is reported in hypertensive patients by some 
studies (8).While others showed increased angiogenic factors in 
serums of hypertensive individuals (9). In other words, impaired 
angiogenesis during embryonic development results in undevel-
oped vascular system that precedes hypertension in later life (6). 
Nicotine is the addictive compound present in tobacco plant and 
in turn smokes (10). Nicotine is an emerging leading cause for car-
diovascular disorders in the most of developed countries (11–13). 
Vascular endothelial dysfunction (VED) has been considered as a 
hallmark of various cardiovascular disorders (14, 15). Long-lasting 
exposure to nicotine induces the risk of VED via decreasing the 
generation and bioavailability of nitric oxide (NO) (16, 17). Mor-
bidity and mortality from cardiovascular disorders are also elevated 
when smoking is associated with hypertension (18). Opioid recep-
tors, including MOR, are expressed on endothelial cells surfaces 
(19) and in the vascular endothelium, morphine activates NO via 
MOR, what in turn leads to vasodilatation(20), promote cell pro-
liferation (20) as well as angiogenesis induced by the endothelial 
cell specifi c growth (21). 
According to the afore mentioned documentary facts in the 
present investigation, we evaluated the effects of addiction to mor-
phine and nicotine as well as chronic hypertension (2K1C) and 
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those withdrawal on blood pressure, coronary angiogenesis and 
serum NO concentration.
Material and methods
Animals
Forty male Wistar rats (aged 10–12 weeks and weightind 
200–250 g) were obtained from the Pasteur Institute of Iran, Teh-
ran. Animals were kept in animal house with 12 h light/dark cycle. 
The animal house temperature was maintained at 20–25 °C. All 
animals had free access to food and water during experiments. The 
ethical committee of the Rafsanjan University of Medical Sciences 
approved the project and animals were handled with care and by 
staff who had animal handling license.
Experimental protocol
Following one week of habituation to animal house, male hy-
pertensive rats were randomly divided into two following groups: 
Group (1): Hypertensive rats that only received solvent of saline 
for 8 weeks (n = 8); Group (2): Hypertensive rats receiving 3 
mg/kg of morphine and 0.01 mg/kg of nicotine for 8 weeks (n 
= 32). At following 8 weeks, the main groups were divided into 
four sub-groups, where hree of the sub-groups (n = 24) were on 
withdrawal: A sub group deprived from morphine (n = 8), A sub 
group deprived from nicotine (n = 8), A sub group deprived from 
both morphine and nicotine (n = 8). After 24 hours of withdrawal, 
rats were treated with naloxone (2 mg/kg). Direct blood pressure 
was measured, blood sample was taken and coronary angiogen-
esis was evaluated.
Induction of hypertension in rats by 2K1C goldblatt method
Initially rats were anesthetized using intraperitoneal ketamine-
hydrochloride (60 mg/kg) and xylazine(7.5 mg/kg). The left kidney 
was exposed via fl ank incision and a silver clip w ithin internal gap 
of 0.2 mm was located around the renal artery. To control the risk 
of infection, rats received prophylactic treatment by penicillin G 
(25000 IU/rat) after surgery. Systolic and diastolic blood pressure 
was measured once a week by a tail-cuff plethysmography under 
light ether anesthesia. Subsequent to 8 weeks of treatment, ani-
mals were anesthetized and direct blood pressure was measured 
by a catheter (PE50), inserted into femoral artery. 
Plasma renin activity 
The plasma renin activity (PRA) was measured using Gamma 
coat PRA Radioimmunoassay kit (DiaSorin Inc). PRA was mea-
sured after withdrawal in hypertensive rats.
Measurement of NO concentration 
The serum concentrations of NO were measured by Griess re-
agent system (Promega Corporation, Madison, USA), using avail-
able reagents as previously described (23). In brief, serums were 
added into wells (96-well enzymatic assay plate). Sulfanilamide 
solution was added to all collected samples and then N-1-naph-
tylethylenediamine dihydrochloride under acidic conditions was 
added. The absorbance was detected by a microplate reader in 
520–550 nm wavelengths. A standard curve was generated and the 
concentration of NO in serum samples was determined by compari-
son to NO standard level. The sensitivity of detection was 2.5 μM.
Evaluation of capillary density 
The tissue samples were obtained from the hearts following 
weeks of the induction of hypertension. Frozen tissue sections 
with 5 μm thickness were prepared from each sample. Endothelial 
cells were stained by immunohistochemical staining methods us-
ing, mose anti-rat CD31 monoclonal antibody (Abcam, Abingdon, 
UK). Capillary density was evaluated by counting twenty random 
microscopic fi elds (magnifi cation × 400) from three different 
sections in each tissue block by three blind examiners. Capillary 
density was expressed as the number of CD31+ cells per square 
millimeter (mm2).
Statistical analysis
One-way ANOVA was used for comparison of data between 
groups. Data are expressed as the mean ± S.E.M. P value less than 
0.05 was considered statistically signifi cant.
Result
Blood pressure
The results of the present study showed lower blood pres-
sure in hypertensive rats, which were addicted to morphine and 
nicotine in comparision to their status before addiction (P<0.05).
After withdrawal, the blood pressure in morphine and nicotine 
withdrawal rats was signifi cantly increased and went back to its 
level of before addiction (p < 0.05) (Fig. 1).
PRA measurement
The PRA levels were measured in all experimental groups 
in nicotine withdrawal animals. The PRA levels were decreased 
compared to control (p < 0.05) (Fig. 2).
Serum NO concentration
Our results showed that there was no signifi cant difference 
in serum NO concentration in pre-addict and addict to concur-
Fig. 1. Demonstrates variations in blood pressure in all experimental 
groups during addiction and withdrawal. * p < 0.05 vs pre-addict. # p 
< 0.05 vs nicotine withdrawal. A) pre-addict, B) addict, C) withdrawal-
morphine, D) withdrawal-nicotine, E) addict-withdrawal
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rent morphine and nicotine group, while after withdrawal, serum 
NO concentration in nicotine withdrawal animals was increased 
and it was signifi cantly higher than pre-addict group (p < 0.05). 
The withdrawal did not improve serum NO level and it was not 
altered compared to addict to concurrent morphine and nicotine 
animals (Fig. 3).
Capillary density
As illustrates in fi gure 5, capillary density (expressed as the 
number of capillary CD31+cell per mm2) was signifi cantly lower 
in morphine and nicotine addicts when compared to pre-addict 
in hypertensive animals (p < 0.05).The addiction withdrawal did 
not alter capillary density in addicted hypertensive rats (p > 0.05).
Representatives of histological sections are shown in (Figs 
4 and 5).
Dis cussion
Previous evidences confi rmed that in the early phase of 2K1C 
hypertensive model, the elevated activity of renin-angiotensin-
aldosterone system is the main responsible mechanisms involved 
in rising blood pressure (24, 25). Although, after 8 weeks of clip-
ping, altered vascular structure is important in maintenance of 
hypertension (24). But chronic morphine treatment showed to 
decline baseline cardiovascular parameters MAP and HR. During 
morphine withdrawal, when naloxone was injected in morphine-
treated rats, MAP and HR (26), systolic and diastolic BP were 
all attenuated (27). Evidences are in fader of the fact that smok-
ing causes induced HR, SBP, DBP, and MBP (28).The increased 
BP following administration of nicotine may possibly be due to 
the induced PRA level (29). And other study demonstrated that 
at baseline, participants had lower resting HR, SBP, and DBP 
during the nicotine withdrawal (30). The results of the current 
study demonstrated that following the withdrawal, BP completely 
went back to the pre-addiction level. The microvascular density 
during development of hypertension have been documented in 
several experimental studies (31–33). Another study performed 
in hypertensive rats showed lower both capillary and arteriolar 
density in the heart of young animals (33). Present results are 
indicative of the fact that coronary angiogenesis decreases in hy-
pertensive rats addicted to both morphine and nicotine. Recent 
evidence pointed to the involvement of morphine in angiogenesis, 
because endothelial cells expressed opioid receptor(s) (34) and 
responded to opiates by increasing intracellular calcium concen-
Fig. 2. Demonstrates PRA values (ng/ml/h) in experimental groups. * 
p < 0.05 vs pre-addict. A) pre-addict, B) addict, C) withdrawal-mor-
phine, D) withdrawal-nicotine, E) addict-withdrawal.
Fig. 3. Demonstrates serum level of NO in experimental groups during 
addiction and withdrawal. * p < 0.05 vs pre-addict. A) pre-addict, B) 
addict, C) withdrawal-morphine, D) withdrawal-nicotine, E) addict-
withdrawal.
Fig. 4. Demonstrates capillary density (expressed as number of cap-
illary/mm2) of heart during addiction and withdrawal. * p < 0.05 vs 
pre-addict. A) pre-addict, B) addict, C) withdrawal-morphine, D) 
withdrawal-nicotine, E) addict-withdrawal.
A
Fig. 5. Depicts a representative photograph of the cross section of the hearts in experimental groups. Original magnifi cation: × 400. A) pre- ad-
dict (control), B) Administration of morphine + nicotine (addict), C) withdrawal-nicotine, D) withdrawal-morphine, E) morphine + nicotine 
withdrawal (addict. withdrawal).
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tration and NO production (35). Accordingly, evidence showed 
that morphine enhanced endothelial cell proliferation and tube 
formation in vitro and increased in vivo blood vessel formation in 
a Matrigel plug assay (34). These studies revealed that morphine 
up regulated angiogenesis in sham and 2K-1C animals via gen-
eration of NO and angiogenesis in hypertensive animals occurred 
much more than what happened in sham group (36). Morphine 
acts both directly and indirectly on angiogenesis (37), however, 
the results are controversial. In contrast to all literature reports 
on the proangiogenic effects of morphine, high concentration of 
morphine is toxic for endothelial cells in vitro (35) and lead to 
oxidative stress-mediated endothelium dysfunction in vivo (38). 
Furthermore, morphine reduced wound healing and mobilization 
of endothelial progenitor cells in mice and decreased the forma-
tion of capillaries in vitro and in vivo matrigel plug assay (39). In 
animals, short-term exposure to nicotine augmented tumor vas-
cularity, plaque neovascularization and retinal angiogenesis (40). 
Nicotine enhanced another type of vasodilating molecule associ-
ated with proliferation, migration and survival of EC (41–43), in 
fact increased angiogenesis. Some other workers suggested that 
nicotine could be toxic to endothelial cells (44), however, these 
observations were made using nicotine overdose, which were 
above clinically relevant concentrations (45). The acute effect of 
nicotine on capillary density was completely abrogated by chronic 
exposure to nicotine. That claimed to be mediated in part by down 
regulation of the vascular α7-nAChR, (an inhibition of NO syn-
thase expression), as well as reduced in plasma VEGF levels (46). 
Accordingly, it appeared that proangiogenic effect of morphine 
and nicotine is dose and phase dependent (40–47). Compelling 
evidences indicated that NO is a critical mediator of angiogenesis. 
And NO has manifold effects on angiogenic processes. NO as a 
proliferative and anti-apoptotic factor served as an endothelial 
survival (48), proliferation factor (49). There is a substantial evi-
dence that showed that effective angiogenesis required the syn-
thesis of bioactive endothelium-derived NO. Firstly, a number of 
angiogenic factors up regulate the endothelial expression of NO 
synthase (NOS) and stimulate the release of endothelium-derived 
NO. Vascular endothelial growth factor (VEGF) augmented the 
endothelial expression of NOS, and stimulated the biosynthesis of 
NO from cultured human umbilical venous endothelial cells (50). 
The serum NO concentrations in 2K1C hypertensive rats were 
lower than sham-clipped group (51).The decreased serum NO 
level could be the result of either endothelial dysfunction due to 
hypertension or adaptation to high blood pressure (52). This and 
decreased NO bioavailability, which was observed in our study, 
could possibly explain why cardiovascular risk factors such as 
hypertension are also considered risk factor for atherosclerosis. 
Reduced NO bioavailability in hypertensive subjects may result 
from lower NO production such as defi ciency in L-arginine/BH4 
(53) or increased NO degradation due to higher superoxide an-
ion generation or reduced level of antioxidant (54).Herein, in this 
study, we did not fi nd any difference in serum NO concentra-
tion between these pre-addict and post-addict hypertensive rats 
surprisingly. That withdrawal of addiction did not alter serum 
NO concentration. Recent studies proposed the presence of spe-
cifi c opioid receptors, including MO on endothelial cells (20). 
Morphine activats NO production in the vascular endothelium 
via attachment to MOR and further leads to vasodilatation (20). 
Opioids also promote cell proliferation (55) and angiogenesis in-
duced by the endothelial cell specifi c growth and survival factor, 
vascular permeability factor/VEGF (56). The chronic exposure to 
nicotine induces VED by decreasing the generation and bioavail-
ability of NO (16) and elevating the level of asymmetric dimethyl 
arginine (ADMA), an endogenous inhibitor of endothelial NOS 
(57). Furthermore, nicotine down-regulates endothelial NOS, an 
enzyme involved in the generation of NO, decreases endothelium 
dependent vasodilatation and induces VED and subsequently ath-
erosclerosis (58). Such fi ndings support the idea that endothelial 
dysfunction and decreased NO generation in coronary artery dis-
ease may play the crucial inhibitory role in the response to anti-
genic agents (59). In conclusion, it seems that changes in blood 
pressure in morphine and nicotine addicted hypertensive rats are 
reversible by withdrawal. That probably suggested that in addi-
tion, other mechanisms could be involved in reversal of blood 
pressure to pre-addict level. Lower coronary angiogenesis during 
addiction and even after withdrawal in our study may propose that 
possible endothelial dysfunction due to co-administration of mor-
phine and nicotine is reminded even post-withdrawal. It shows 
the importance of addiction treatment of morphine and nicotine 
in hypertension in clinical condition.
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